Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Nürnberg – page 31

505 clinical trials in Nürnberg, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Nürnberg at a glance
505
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

505 trials in Nürnberg

Open in trial search

Adenocarcinoma gastric+1

Not recruiting

Study Comparing Ramucirumab with Irinotecan, Leucovorin, and 5-FU or Paclitaxel for Patients with Advanced Stomach or Gastroesophageal Cancer After Previous Chemotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Plasma cell myeloma

Not recruiting

Comparison of intravenous versus subcutaneous isatuximab with lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma patients eligible for transplant

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Rectal cancer

Not recruiting

Study Comparing FOLFOX Before Surgery to Risk-Adapted Chemotherapy After Surgery for Patients with Locally Advanced Rectal Cancer and Low Risk of Local Failure

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Heidelberg University

Study of Venetoclax and Blinatumomab for Adults with Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Blinatumomab
  • Sponsor:Goethe University Frankfurt

Study of Prednisolone and SPI-62 for Patients with Polymyalgia Rheumatica

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Clofutriben
  • Sponsor:Sparrow Pharmaceuticals Inc.

Hidradenitis

Not recruiting

Study of lutikizumab compared to placebo in adults and adolescents (age 12 and older) with moderate to severe Hidradenitis Suppurativa

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Lutikizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on De-escalated Induction Therapy with Methotrexate, Cytarabine, Thiotepa, and Rituximab for Newly Diagnosed Primary CNS Lymphoma Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Busulfan
  • Sponsor:Klinikum Der Landeshauptstadt Stuttgart gKAöR

Colitis ulcerative

Not recruiting

Study on the Effects of Fecal Microbiome and Fecal Microbiome Filtrate Capsules for Patients with Active Ulcerative Colitis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Metronidazole
  • Sponsor:Friedrich-Schiller-Universitaet Jena

B-cell lymphoma

Not recruiting

Study of Rituximab, Polatuzumab Vedotin, and Glofitamab for Untreated Aggressive B-cell Lymphoma in Patients Over 60 Not Eligible for Full R-CHOP

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Glofitamab
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Study comparing chemotherapy with or without radiation therapy in patients with resectable gastroesophageal junction cancer using docetaxel, oxaliplatin, fluorouracil and calcium folinate

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Heidelberg University

Study Comparing Volrustomig with Chemotherapy to Pembrolizumab with Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Study on Ixekizumab for Rapid Pain Relief in Patients with Axial Spondyloarthritis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ixekizumab
  • Sponsor:Universitaetsklinikum Erlangen AöR

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Nürnberg

What the registry says about research in the country

01 Oncology Research

Groundbreaking trials focused on treating multiple myeloma, breast cancer, and melanoma. Studies evaluate novel therapies including CAR T-cell treatments and targeted immunotherapies.

  • Multiple Myeloma Treatments
  • Breast Cancer Therapies
  • Melanoma Management

Advanced research includes investigation of new combination therapies and maintenance treatments post-transplantation.

02 Cardiovascular Studies

Innovative research targeting atherosclerotic cardiovascular disease and related conditions. Trials evaluate new medications for managing cholesterol and reducing major cardiovascular events.

  • Cholesterol Management
  • Cardiovascular Risk Reduction
  • Pulmonary Embolism Treatment

Focus on developing treatments to improve patient outcomes in cardiovascular conditions.

03 Immunology and Inflammation

Clinical studies examining treatments for inflammatory myopathies and psoriatic arthritis. Research focuses on innovative therapies and disease management approaches.

  • Inflammatory Disease Treatment
  • Autoimmune Conditions
  • Immunotherapy Applications

Emphasis on developing targeted treatments for severe inflammatory conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.